Medicus Pharma advances pipeline during Q2 with key milestones

Medicus Pharma (NASDAQ:MDCX) has reported second quarter financial results and regulatory and clinical progress across its SkinJect and Teverelix programs, while raising about $40 million through equity and debt financing during the first half of 2026. The company said it received FDA “Study May Proceed” authorization for its registrational SkinJect study in patients with Gorlin Syndrome. Its Teverelix program received Institutional Review Board authorization and positive FDA feedback for an optimized Phase 2 study in acute urinary retention, while the company also received UAE Department of Health authorization to begin the PRECISION-E2 Phase 2 study evaluating Teverelix in women with symptomatic endometriosis.

For SkinJect, Medicus reported additional pre-specified analyses from its completed Phase 2 SKNJCT-003 study, showing clinical and histological clearance rates of 64% and 55%, respectively, at the 200 microgram dose. The company said the FDA authorization allows it to init...